In 1973, Glatt Pharmaceutical Services opened its first CDMO site in Ramsey, New Jersey, with a bold vision to revolutionize drug development. Just two years later, the company earned its first FDA approval, marking the beginning of a journey that would transform it into a global leader.
In 1997, Glatt Pharmaceutical Services took a pivotal step by establishing a CDMO site at its headquarters in Binzen, Germany. This state-of-the-art facility quickly gained EMEA approval in 1998, followed by FDA approval in 2006, positioning Glatt Pharmaceutical Services as a reliable partner for the pharmaceutical industry in both the U.S. and Europe.
Specializing in the galenic development of oral solid dosage forms, Glatt Pharmaceutical Services‘ expertise lies in multiparticulate systems like pellets or micropellets. From early clinical trials to full-scale commercial production, their robust formulation processes ensure seamless scalability. Whether customers need a single service or a full package, Glatt Pharmaceutical Services delivers high-quality solutions tailored to their needs.
With FDA- and EU-approved sites operating under cGMP conditions, Glatt Pharmaceutical Services guarantees excellence at every stage, from development to commercial manufacturing. Today, as a global leader, Glatt Pharmaceutical Services continues to drive innovation, offering reliability and quality across the pharmaceutical landscape.